Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3511707 | 0.76 | NPC1 (0.53) | KMT2AMEN1KDM4CL3MBTL1NPC1 | |
| SCHEMBL11994833 | 0.75 | MEN1 (0.47) | KMT2AMEN1KDM4CL3MBTL1NPC1 | |
| SCHEMBL3511939 | 0.74 | KDM4C (0.56) | KMT2AMEN1KDM4CL3MBTL1NPC1 | |
| SCHEMBL2644185 | 0.74 | KMT2A (0.51) | KMT2AMEN1KDM4CL3MBTL1NPC1 | |
| SCHEMBL29055398 | 0.72 | MEN1 (0.49) | KMT2AMEN1KDM4CL3MBTL1NPC1 | |
| SCHEMBL17288212 | 0.72 | KDM4C (0.53) | KMT2AMEN1KDM4CL3MBTL1NPC1 | |
| SCHEMBL5197679 | 0.72 | MEN1 (0.51) | KMT2AMEN1KDM4CL3MBTL1NPC1 | |
| SCHEMBL29055399 | 0.71 | MEN1 (0.51) | KMT2AMEN1KDM4CL3MBTL1NPC1 | |
| SCHEMBL29703979 | 0.70 | MEN1 (0.53) | KMT2AMEN1KDM4CL3MBTL1NPC1 | |
| SCHEMBL12343371 | 0.70 | MEN1 (0.47) | KMT2AMEN1KDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572670-B1 | 5-SUBSTITUTED-PYRAZINE OR -PYRIDINE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2007-08-22 | — | — | EP | disclosed |
| US-7132425-B2 | 5-substituted-six-membered heteroaromatic glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1572670-A1 | 5-SUBSTITUTED-PYRAZINE OR -PYRIDINE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| US-20040147748-A1 | 5-Substituted-six-membered heteroaromatic glucokinase activators | CHEN SHAOQING (US) | 2004-07-29 | — | — | US | disclosed |
| WO-2004052869-A1 | 5-SUBSTITUTED-PYRAZINE OR PYRIDINE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147748-A1 | 5-Substituted-six-membered heteroaromatic glucokinase activators | GCK, GCKR, GALK1 | KMT2A 2865/4885MEN1 3461/4885KDM4C 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.